source
- Biogen advances tau-targeting Alzheimer drug to Phase 3 despite mixed Phase 2 dataBiogen reported results from a Phase 2 trial of its tau-targeting Alzheimer’s candidate diranersen (BIIB080). The study measured tau levels in cerebrospinal fluid and brain tissue of patients with…
- FDA commissioner Marty Makary exits, acting head Kyle Diamantas named as podcast discusses impact and Senate health raceThe Readout Loud podcast episode focused on health politics, featuring a discussion of FDA commissioner Marty Makary's departure. Hosts examined why Makary is leaving, which of his policies might…